Atorvastatin (HMG-CoA) + chemotherapy shows 70.3% tumor-marker declines in advanced PDAC

Atorvastatin, an HMG-CoA reductase inhibitor (statin), was paired with chemotherapy after a 260-line PDAC organoid biobank tied chemoresistance to cholesterol/glycosylation programs and showed statins could re-sensitize organoids. In a single-center, single-arm Phase 2 (NCT06241352) for advanced PDAC (n=37), 70.3% had >20% tumor-marker declines (and ~25% had >50% decrease); RECIST responses and detailed safety were not reported. For context, first-line FOLFIRINOX and nab-paclitaxel+gemcitabine yield RECIST ORR ≈31.6% and 23% with mOS 11.1 and 8.5 months, respectively—so these biomarker responses aren’t directly comparable but may indicate biological activity given CA19-9 decline’s association with survival.